Botulinum neurotoxin type A, which has been reported to have antitumor effects, augments the efficacy of PD‐1 inhibitors on MC38 tumors through reducing serum exosome levels and improving the population of tumor‐infiltrating CD4+ and CD8+ T lymphocytes.431. Here, CD8A is linked to neoplasm.